Welcome to BioSeeker Group!

Melanoma Therapeutics: Which Strategy Will Take Us There?

Additional Information

Published Date Jul 18, 2005
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 204
PDF Fact Sheet View Fact Sheet for the report Melanoma Therapeutics: Which Strategy Will Take Us There? in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$2,450.00

Quick Overview

Melanoma drug development has and will continue to have a strong focus on target therapy such as vaccines, monoclonal antibodies, dendritic cells, and gene therapy.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Melanoma Therapeutics: Which Strategy Will Take Us There?.

    To find out more about Melanoma Therapeutics: Which Strategy Will Take Us There?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Melanoma Therapeutics: Which Strategy Will Take Us There? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Executive Summary

Melanoma drug development has and will continue to have a strong focus on target therapy such as vaccines, monoclonal antibodies, dendritic cells, and gene therapy. In recent years, immunologic strategies including tumor vaccine and adjuvant therapy with interferon-alfa have been attempted to improve survival of patients with more advanced malignant melanoma. Another emerging strategy in anticancer therapy is the targeting of chemotherapy resistance by overcoming the antiapoptosis mechanisms of cancer cells. An example of this approach is the novel antisense oligonucleotide Genasense® that targets the antiapoptotic gene bcl-2. Recently, Genta initiated a European regulatory submission for Genasense® plus chemotherapy for patients with advanced melanoma by sending a letter of intent to EMEA for Marketing Authorization Application. This in-depth analysis, 200+ pages and almost 100 figures, tables and boxes, deals with the current therapy strategies employed and opportunities for increased pharmaceutical intervention, in the context of the present competitive landscape for malignant melanoma.

 

This report covers the latest on

  • Disease overview, including incidence, unmet needs, risk factors, screening and diagnosis.
  • Analysis of current treatment and key therapeutic strategies, including surgery, immunotherapy, vaccines and combination therapies.
  • Includes product profiles of key drugs by class.
  • Progress analysis on more than 60 pipeline products, including emerging and hot pre-clinical data, discontinued projects, clinical trial information, commercial potential and limiting factors.
  • Competitive landscape analysis, including extensive lay-out of competitors with collaborations, licensing, M&A etc, major highlights, trends and company profiles on more than 50 of the most important companies in melanoma.

List of Figures

List of Tables

List of Boxes

Methodology

Etiology and Pathophysiology

Key Therapy Strategies

Immunotherapy

Cancer Vaccines

Antiangiogenesis

Gene Therapy

Current Treatment Regimens

An Overview

Cytotoxic Drugs

Dacarbazine

Cisplatin

Carboplatin

Carmustine

Melphalan

Paclitaxel

Tamoxifen

Temozolomide

Vinblastine/Vinorelbine

Biological treatments

Virulizin

Melacine

Alfanative (Multiferon)

Proleukin or (Macrolin)

Ceplene Maxamine

Competitive Lanscape in Melanoma R&D

Phase I & II R&D Collaborations in Melanoma: Oxxon

Roche links Schering-Plough and Chugai Clusters Together - What Will the Outcome Be?

GlaxoSmithKline Brings Wyeth, Hayashibara, Cytokinetics and Coley Pharmaceuticals Together

GlaxoSmithKline and Sanofi-Aventis have a Joint Middle Man

R&D Collaboration Trends in Melanoma Projects

Current Melanoma Drug Development

Vaccines: Active Immunotherapy a Benefit or Not?

Vaccine: Direct Immunization with Tumor Antigens

Vaccines: Is the Development of Cell Therapy Stalling?

DNA Vaccine

Vaccine Adjuvants

Immunostimulants: The Push in Passive Immunotherapy

Immuno-Biologicals: The Work Horse

Immunostimulation by Gene Therapy

One Small Molecular Drug Candidate

Antiongiogenesis- The Major Research Focus for the Next Decade?

Apoptosis Inducers: Moving into Market

Small Molecules Inhibiting Cell Growth Faces Difficulties

Other Biological Drugs

Disclaimer

Selected Company Profiles

Index

Appendix I: Treatment Guide Lines Melanoma

BioSeeker has identified more than 120 companies within the sphere of melanoma and we have listed the biggest players within this field below:
Abgenix
Actis Biologics
Ajinomoto
Amgen
Anosys
Antigen Express
Antigenics
Antisense Pharma
Applied Molecular Evolution
Arriani
AVAX Technologies
Avidex
BASF
Bayer
Biokine
bioMerieux
Biomira
Bioniche
BioNumerik
BioWa
BioVex
Bristol-Myers Squibb
Callisto
CancerVax
Celgene
CelSci
Chiron
Chugai
CJ Corp
Clavis
Coley Pharmaceutical
Corixa
CSL
Curacyte
CuraGen
Cytokinetics
Discovery Laboratories
Elan
ELEA
Enichimica
EntreMed
Enzon
GemVax
Genencor
Genentech
Generex Biotechnology
Genetronics
GenQuest
Genta
Genzyme
Gilead Sciences
GlaxoSmithKline
GlobeImmune
Hayashibara
IDM
ImClone Systems
Inotek
Intercell
Intracel
Introgen
Juvaris
KeyCell
Kirin Brewery
KOSAN
KuDOS
Kyowa Hakko
Ligand
Lilly
Lorus Therapeutics
Maxim
Medarex
Medigen Biotechnology
MedImmune
Megapharm
Merck KGaA
Mojave
Myriad
Novartis
Novo Nordisk
Onyx
Orient Europharma
Oxxon
Pfizer
PharmaMar
Pharmexa
Pierre Fabre
Pisa
Point Therapeutics
Progen
Inovio Biomedical Corporation
RegeneRx
Roche
Russian Biotechnologies
Sanofi-aventis
Scancell
Schering-Plough
SciClone
Sclavo
Sequenom
Serono
Sigma-Tau
T-cellic
Therion Biologics
Titan
Transgene
Valentis
VaxGen
Vernalis
Vical
Viragen
ViraNative
Viventia Biotech
Wyeth
ZymoGenetics and more.
Example of candidate drugs included:
AP 12009
BAY 504798
Bevacizumab
CANVAXIN
CP 4055
DISC-GMCSF
Endostatin
HSPPC 96
Iboctadekin
INO 1001
MEL-VAC
MTI 506
MTI SAM3
MX 128495
Oblimersen
ONCOFLU
OncoVax
OncoVEX GM-CSF
Peginterferon alfa-2b
PI 88
SGN 17/19
TC 101C
TG 1041
TRANSVAX
UVIDEM
VITAXIN MAb and many more.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Melanoma Therapeutics: Which Strategy Will Take Us There?.
    To find out more about Melanoma Therapeutics: Which Strategy Will Take Us There?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Melanoma Therapeutics: Which Strategy Will Take Us There? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place
This report comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. The report extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer. Significantly new breast cancer therapies will soon come to challenge old established drugs on the market. Learn More


Cancer Peptides: From First-in-Class to Best-in-Class?
In-depth pipeline analytics of peptide drugs in oncology showing you where the Competition is, What is first-in-class and Is First-in-Class the Best-in-Class?, Indication expansion opportunities and much more Learn More

Other selected research from the 'R&D' category:


HCV R&D and Business Development Database
This CD-ROM product is one of the most comprehensive and up to date information sources on chronic hepatitis C virus R&D and business development. Learn More


Biosimilars in Oncology Drug Pipeline Update
BioSeeker Group have identified 90 companies plus partners who are today developing 213 biosimilar drugs in 472 developmental projects in cancer across 17 different targets. In addition, there is 1 suspended drug and another 1 drugs where development has been ceased. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Leukemia, Pancreatic Cancer and Peptides
This triple analysis focuses on cancer drug development strategies in both Leukemia and Pancreatic Cancer and by the compound strategy of Peptides. Learn More


Triple Analysis: Melanoma, Apoptosis and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines. Learn More